B-cell CLL/lymphoma 3 promotes glioma cell proliferation and inhibits apoptosis through the oncogenic STAT3 pathway

Wu,Jianheng; Li,Linfan; Jiang,Guangyuan; Zhan,Hui; Wang,Nannan

doi:10.3892/ijo.2016.3729

B-cell CLL/lymphoma 3 promotes glioma cell proliferation and inhibits apoptosis through the oncogenic STAT3 pathway

Authors:
- Jianheng Wu
- Linfan Li
- Guangyuan Jiang
- Hui Zhan
- Nannan Wang
View Affiliations

Affiliations: Department of Neurosurgery, The People's Hospital of Gaozhou, Gaozhou, Guangdong 525200, P.R. China, Department of Neurosurgery, The Second People's Hospital of Guangxi Zhuang Autonomous Region, Guilin 541000, P.R. China, Department of Gastroenterology, The People's Hospital of Gaozhou, Gaozhou, Guangdong 525200, P.R. China
Published online on: October 12, 2016 https://doi.org/10.3892/ijo.2016.3729
Pages: 2471-2479

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aberrant expression of oncogenes and/or tumor suppressors play fundamental roles in the pathogenesis of glioma. B-cell CLL/lymphoma 3 (BCL3) was previously found to be a putative proto-oncogene in human cancers and the decoy receptor DcR1 is induced in a p50/Bcl3-dependent manner and attenuates the efficacy of temozolomide in glioblastoma cells. However, its expression status, clinical significance and biological functions in glioma remain largely unknown. In the present study, the levels of BCL3 were overexpressed in glioma compared to normal brain tissues. Furthermore, high expression of BCL3 protein was confirmed by immunoblotting in glioma cells as compared with normal human astrocyte cell line. The positive expression of BCL3 was correlated with adverse prognostic features and reduced overall survival rate of glioma patients. BCL3 silencing resulted in prominent decreased proliferation, cell cycle arrest in G1 phase and increased apoptosis in U251 cells. In contrast, BCL3 overexpression in U87 cells remarkably facilitated proliferative ability and cell cycle progression and induced apoptosis. In vivo studies showed that BCL3 knockdown inhibited the tumor growth of U251 cells in a mouse xenograft model. Mechanistically, BCL3 positively regulated the abundance of STAT3, p-STAT3 and the downstream targets of STAT3 pathway including BCL2, MCL-1 and cyclin D1 in glioma cells. Furthermore, a positive correlation between BCL3 and STAT3 expression was observed in glioma specimens. Notably, we confirmed that STAT3 knockdown abolished the oncogenic roles of BCL3 in glioma. In conclusion, we suggest that BCL3 serves as an oncogene in glioma by modulating proliferation, cell cycle progression and apoptosis, and its oncogenic effects are mediated by the STAT3 signaling pathway.

View Figures

View References

1	Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V, et al: Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 514:628–632. 2014. View Article : Google Scholar : PubMed/NCBI
2	Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari FB, et al: Cancer-associated protein kinase C mutations reveal kinase’s role as tumor suppressor. Cell. 160:489–502. 2015. View Article : Google Scholar : PubMed/NCBI
3	Chistiakov DA and Chekhonin VP: Extracellular vesicles shed by glioma cells: Pathogenic role and clinical value. Tumour Biol. 35:8425–8438. 2014. View Article : Google Scholar : PubMed/NCBI
4	Zhang XQ and Leung GK: Long non-coding RNAs in glioma: Functional roles and clinical perspectives. Neurochem Int. 77:78–85. 2014. View Article : Google Scholar : PubMed/NCBI
5	Chautard E, Ouédraogo ZG, Biau J and Verrelle P: Role of Akt in human malignant glioma: From oncogenesis to tumor aggressiveness. J Neurooncol. 117:205–215. 2014. View Article : Google Scholar : PubMed/NCBI
6	Katsetos CD, Reginato MJ, Baas PW, D’Agostino L, Legido A, Tuszyn Ski JA, Dráberová E and Dráber P: Emerging microtubule targets in glioma therapy. Semin Pediatr Neurol. 22:49–72. 2015. View Article : Google Scholar : PubMed/NCBI
7	Awad AJ, Burns TC, Zhang Y and Abounader R: Targeting MET for glioma therapy. Neurosurg Focus. 37:E102014. View Article : Google Scholar : PubMed/NCBI
8	Huse JT and Aldape KD: The evolving role of molecular markers in the diagnosis and management of diffuse glioma. Clin Cancer Res. 20:5601–5611. 2014. View Article : Google Scholar : PubMed/NCBI
9	Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K and Siebenlist U: The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers. Cell. 72:729–739. 1993. View Article : Google Scholar : PubMed/NCBI
10	Cogswell PC, Guttridge DC, Funkhouser WK and Baldwin AS Jr: Selective activation of NF-kappa B subunits in human breast cancer: Potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene. 19:1123–1131. 2000. View Article : Google Scholar : PubMed/NCBI
11	Choi HJ, Lee JM, Kim H, Nam HJ, Shin HJ, Kim D, Ko E, Noh DY, Kim KI, Kim JH, et al: Bcl3-dependent stabilization of CtBP1 is crucial for the inhibition of apoptosis and tumor progression in breast cancer. Biochem Biophys Res Commun. 400:396–402. 2010. View Article : Google Scholar : PubMed/NCBI
12	Thornburg NJ, Pathmanathan R and Raab-Traub N: Activation of nuclear factor-kappaB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res. 63:8293–8301. 2003.PubMed/NCBI
13	Pallares J, Martínez-Guitarte JL, Dolcet X, Llobet D, Rue M, Palacios J, Prat J and Matias-Guiu X: Abnormalities in the NF-kappaB family and related proteins in endometrial carcinoma. J Pathol. 204:569–577. 2004. View Article : Google Scholar : PubMed/NCBI
14	Tu K, Liu Z, Yao B, Xue Y, Xu M, Dou C, Yin G and Wang J: BCL-3 promotes the tumor growth of hepatocellular carcinoma by regulating cell proliferation and the cell cycle through cyclin D1. Oncol Rep. 35:2382–2390. 2016.PubMed/NCBI
15	Puvvada SD, Funkhouser WK, Greene K, Deal A, Chu H, Baldwin AS, Tepper JE and O’Neil BH: NF-κB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology. 78:181–188. 2010. View Article : Google Scholar :
16	Liu Z, Jiang Y, Hou Y, Hu Y, Cao X, Tao Y, Xu C, Liu S, Wang S, Wang L, et al: The IκB family member Bcl-3 stabilizes c-Myc in colorectal cancer. J Mol Cell Biol. 5:280–282. 2013. View Article : Google Scholar : PubMed/NCBI
17	Maldonado V, Espinosa M, Pruefer F, Patiño N, Ceballos-Canciono G, Urzua U, Juretic N and Melendez-Zajgla J: Gene regulation by BCL3 in a cervical cancer cell line. Folia Biol (Praha). 56:183–193. 2010.
18	Mansour NM, Bernal GM, Wu L, Crawley CD, Cahill KE, Voce DJ, Balyasnikova IV, Zhang W, Spretz R, Nunez L, et al: Decoy receptor DcR1 is induced in a p50/Bcl3-dependent manner and attenuates the efficacy of temozolomide. Cancer Res. 75:2039–2048. 2015. View Article : Google Scholar : PubMed/NCBI
19	Pessôa IA, Sagica FE, Anselmo NP, Brito JR and de Oliveira EH: IDH1 and IDH2 mutations in different histologic subtypes and WHO grading gliomas in a sample from Northern Brazil. Genet Mol Res. 14:6533–6542. 2015. View Article : Google Scholar : PubMed/NCBI
20	Tu K, Li J, Verma VK, Liu C, Billadeau DD, Lamprecht G, Xiang X, Guo L, Dhanasekaran R, Roberts LR, et al: Vasodilator-stimulated phosphoprotein promotes activation of hepatic stellate cells by regulating Rab11-dependent plasma membrane targeting of transforming growth factor beta receptors. Hepatology. 61:361–374. 2015. View Article : Google Scholar
21	Cipriano R, Miskimen KL, Bryson BL, Foy CR, Bartel CA and Jackson MW: Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer. Mol Cancer Res. 12:1156–1165. 2014. View Article : Google Scholar : PubMed/NCBI
22	Li H, Liu YW, Wang H, Zhou Q, Li JJ, Annie H, Qi ST and Lu YT: MiR-519a functions as a tumor suppressor in glioma by targeting the oncogenic STAT3 pathway. J Neurooncol. 128:35–45. 2016. View Article : Google Scholar
23	Hartel I, Ronellenfitsch M, Wanka C, Wolking S, Steinbach JP and Rieger J: Activation of AMP-activated kinase modulates sensitivity of glioma cells against epidermal growth factor receptor inhibition. Int J Oncol. 49:173–180. 2016.PubMed/NCBI
24	Foster KA, Jane EP, Premkumar DR, Morales A and Pollack IF: NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5. Int J Oncol. 47:506–516. 2015.PubMed/NCBI
25	Wang H, Wang Y, Bao Z, Zhang C, Liu Y, Cai J and Jiang C: Hypomethylated Rab27b is a progression-associated prognostic biomarker of glioma regulating MMP-9 to promote invasion. Oncol Rep. 34:1503–1509. 2015.PubMed/NCBI
26	Guan Y, Yao H, Zheng Z, Qiu G and Sun K: MiR-125b targets BCL3 and suppresses ovarian cancer proliferation. Int J Cancer. 128:2274–2283. 2011. View Article : Google Scholar
27	Wu ZL, Song YQ, Shi YF and Zhu J: High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma. J Hematol Oncol. 4:312011. View Article : Google Scholar : PubMed/NCBI
28	Chen Y, Wang J, Wang X, Liu X, Li H, Lv Q, Zhu J, Wei B and Tang Y: STAT3, a poor survival predicator, is associated with lymph node metastasis from breast cancer. J Breast Cancer. 16:40–49. 2013. View Article : Google Scholar : PubMed/NCBI
29	Takemoto S, Ushijima K, Kawano K, Yamaguchi T, Terada A, Fujiyoshi N, Nishio S, Tsuda N, Ijichi M, Kakuma T, et al: Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinoma. Br J Cancer. 101:967–972. 2009. View Article : Google Scholar : PubMed/NCBI
30	Brantley EC and Benveniste EN: Signal transducer and activator of transcription-3: A molecular hub for signaling pathways in gliomas. Mol Cancer Res. 6:675–684. 2008. View Article : Google Scholar : PubMed/NCBI
31	Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, et al: A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. 26:2435–2444. 2007. View Article : Google Scholar